{
  "id": 2951027,
  "title": "Citi Predicts Up to 410% Rally for These 2 ‘Strong Buy’ Stocks",
  "url": "https://urgent.news/2026/08/22/citi-predicts-up-to-410-rally-for-these-2-strong-buy-stocks",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-22T18:05:00.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/markets/stocks/articles/citi-predicts-410-rally-2-180500861.html"
  },
  "original_language": "en",
  "account": "Citi analyst Yigal Nochomovitz predicts triple-digit gains for Biomea Fusion (BMEA), a clinical-stage biopharmaceutical company developing treatments for diabetes and obesity. Biomea has two drug candidates in the pipeline, Icovamenib and BMF-650, which target beta-cell function in diabetes and obesity, respectively. In a Phase II study, Icovamenib showed a statistically significant improvement in HbA1c levels compared to placebo, and no serious adverse events were reported. Biomea is also conducting a Phase I trial for BMF-650, a near-oral GLP-1 receptor agonist, which has demonstrated promising results in preclinical studies. Nochomovitz rates BMEA shares a Buy with a $7 price target, expecting a 410% increase over the next twelve months as the company's pipeline and market potential continue to grow.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}